AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+4.92%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$390M
AUM Growth
+$390M
(-4.4%)
Cap. Flow
-$27.1M
Cap. Flow
% of AUM
-6.96%
Top 10 Holdings %
Top 10 Hldgs %
82.6%
Holding
55
New
7
Increased
8
Reduced
8
Closed
12
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$8.51M |
| 2 |
Merck
MRK
|
$7.84M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$2.98M |
| 4 |
Celldex Therapeutics
CLDX
|
$2.79M |
| 5 |
Soleno Therapeutics
SLNO
|
$2.18M |
Top Sells
| 1 |
AbbVie
ABBV
|
$16.5M |
| 2 |
argenx
ARGX
|
$8.21M |
| 3 |
Cytokinetics
CYTK
|
$6.28M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$4.69M |
| 5 |
Insmed
INSM
|
$4.34M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$3B
| $1.56M | 0.3% |
40,000
| – | – |
|
|
MREO
27
Mereo BioPharma
MREO
$278M
| $1.52M | 0.29% |
421,359
| – | – |
|
28
Charles River Laboratories
CRL
$7.88B
| $1.43M | 0.28% |
6,905
| – | – |
|
29
Kura Oncology
KURA
$692M
| $1.18M | 0.23% |
57,178
+17,700
| +45% | +$364K |
|
30
NewAmsterdam Pharma
NAMS
$2.73B
| $1.04M | 0.2% |
54,285
| – | – |
|
31
Ascendis Pharma
ASND
$12.2B
| $1.01M | 0.2% |
7,440
-8,454
| -53% | -$1.15M |
|
|
SLN
32
Silence Therapeutics
SLN
$231M
| $997K | 0.19% |
52,476
| – | – |
|
33
Syndax Pharmaceuticals
SNDX
$1.39B
| $991K | 0.19% |
+48,263
| New | +$991K |
|
34
Keros Therapeutics
KROS
$635M
| $914K | 0.18% |
+20,000
| New | +$914K |
|
35
Corbus Pharmaceuticals
CRBP
$118M
| $905K | 0.17% |
+20,000
| New | +$905K |
|
36
EyePoint Pharmaceuticals
EYPT
$811M
| $883K | 0.17% |
101,500
+50,000
| +97% | +$435K |
|
37
Annexon
ANNX
$229M
| $723K | 0.14% |
147,485
| – | – |
|
38
Larimar Therapeutics
LRMR
$324M
| $656K | 0.13% |
90,490
+32,300
| +56% | +$234K |
|
39
Disc Medicine
IRON
$2.08B
| $606K | 0.12% |
13,440
-73,600
| -85% | -$3.32M |
|
40
Pliant Therapeutics
PLRX
$98.2M
| $538K | 0.1% |
50,000
-50,000
| -50% | -$538K |
|
41
Madrigal Pharmaceuticals
MDGL
$9.65B
| $436K | 0.08% |
1,557
| – | – |
|
42
Sarepta Therapeutics
SRPT
$1.78B
| $411K | 0.08% |
+2,600
| New | +$411K |
|
|
43
AbbVie
ABBV
$372B
| – | – |
-90,821
| Closed | -$16.5M |
|
44
Arvinas
ARVN
$568M
| – | – |
-40,000
| Closed | -$1.65M |
|
45
Biomea Fusion
BMEA
$119M
| – | – |
-35,452
| Closed | -$530K |
|
|
46
Cytokinetics
CYTK
$5.74B
| – | – |
-89,525
| Closed | -$6.28M |
|
47
Immunovant
IMVT
$2.63B
| – | – |
-21,397
| Closed | -$691K |
|
48
Janux Therapeutics
JANX
$1.36B
| – | – |
-47,949
| Closed | -$1.81M |
|
49
MacroGenics
MGNX
$119M
| – | – |
-64,007
| Closed | -$942K |
|
50
RAPT Therapeutics
RAPT
$195M
| – | – |
-137,308
| Closed | -$1.23M |
|